Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for PTC Therapeutics, driven by higher revenues, with a focus on how actual results will compare to estimates [1][2]. Financial Expectations - PTC Therapeutics is expected to report a quarterly loss of $0.21 per share, reflecting a year-over-year change of +12.5% [3]. - Revenues are projected to be $304.72 million, representing a 43% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 15.33% higher in the last 30 days, indicating a positive reassessment by analysts [4]. - The Most Accurate Estimate for PTC Therapeutics is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +133.56% [12]. Earnings Surprise Prediction - A positive Earnings ESP is a strong indicator of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [10]. - PTC Therapeutics has a Zacks Rank of 3, suggesting a likelihood of beating the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, PTC Therapeutics was expected to post a loss of $1.19 per share but instead reported earnings of $0.20, achieving a surprise of +116.81% [13]. - The company has beaten consensus EPS estimates in each of the last four quarters [14]. Industry Context - In the Zacks Medical - Biomedical and Genetics industry, BioMarin Pharmaceutical is expected to post earnings of $0.25 per share, indicating a year-over-year change of -72.8% [18]. - BioMarin's revenue is expected to be $829.66 million, up 11% from the previous year, but the consensus EPS estimate has been revised 1.2% lower [19].

Core Viewpoint - Wall Street anticipates a year-over-year decline in earnings for RE/MAX, with a consensus estimate of $0.28 per share, reflecting a -6.7% change, and revenues expected to be $71.25 million, down 1.7% from the previous year [3]. Earnings Report Expectations - The earnings report is scheduled for February 19, and if the actual results exceed expectations, the stock may rise; conversely, missing estimates could lead to a decline [2]. - Management's discussion during the earnings call will significantly influence the sustainability of any immediate price changes and future earnings expectations [2]. Estimate Revisions and Predictions - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [4]. - The Zacks Earnings ESP model shows a positive Earnings ESP of +14.29% for RE/MAX, suggesting analysts have recently become more optimistic about the company's earnings prospects [12]. Historical Performance - RE/MAX has a history of beating consensus EPS estimates, having done so in the last four quarters, including a +2.78% surprise in the most recent quarter [13][14]. - The stock currently holds a Zacks Rank of 3, indicating a neutral outlook [12]. Investment Considerations - While a positive earnings surprise is a strong predictor of stock performance, other factors can also influence stock movement, making it essential to consider the broader context [15][17]. - Investors are encouraged to utilize the Earnings ESP and Zacks Rank to identify potential investment opportunities ahead of earnings releases [16].

Core Viewpoint - Teck Resources Ltd is expected to report a year-over-year increase in earnings and revenues for the quarter ended December 2025, with a consensus outlook indicating a potential impact on stock price based on actual results compared to estimates [1][2]. Earnings Expectations - The consensus EPS estimate for Teck Resources is $0.56 per share, reflecting a year-over-year increase of +69.7% [3]. - Revenues are projected to be $2.02 billion, which is an increase of 1.4% from the same quarter last year [3]. Estimate Revisions - The EPS estimate has been revised 15.18% higher in the last 30 days, indicating a positive reassessment by analysts [4]. - The Most Accurate Estimate for Teck Resources is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +21.63% [12]. Earnings Surprise History - In the last reported quarter, Teck Resources had an earnings surprise of +41.03%, reporting $0.55 per share against an expected $0.39 [13]. - The company has beaten consensus EPS estimates in all of the last four quarters [14]. Industry Comparison - Another company in the mining sector, Reliance, is expected to report earnings of $2.8 per share, with a year-over-year change of +26.1% and revenues of $3.38 billion, up 8.2% from the previous year [18][19]. - Reliance's EPS estimate has been revised 0.3% higher, resulting in an Earnings ESP of +2.59% [19].

Core Viewpoint - The market anticipates Pool Corp. (POOL) will report a year-over-year increase in earnings driven by higher revenues for the quarter ending December 2025, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - The upcoming earnings report is expected on February 19, with a consensus estimate of $0.99 per share, reflecting a year-over-year increase of +2.1%. Revenues are projected to be $998.27 million, up 1.1% from the previous year [3][2]. Estimate Revisions - The consensus EPS estimate has been revised 0.07% higher in the last 30 days, indicating a positive reassessment by analysts [4]. Earnings Surprise Prediction - The Most Accurate Estimate for Pool Corp. is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +1.01%, suggesting a bullish outlook from analysts [12]. Historical Performance - In the last reported quarter, Pool Corp. exceeded the expected earnings of $3.38 per share by delivering $3.39, resulting in a surprise of +0.30%. Over the last four quarters, the company has beaten consensus EPS estimates three times [13][14]. Investment Considerations - While a potential earnings beat is a positive indicator, other factors may influence stock performance, making it essential to consider the broader context [15][17].

Company Overview - Texas Roadhouse (TXRH) is anticipated to report a year-over-year decline in earnings of 11.6%, with expected earnings of $1.53 per share for the quarter ended December 2025 [3]. - The company's revenues are projected to reach $1.5 billion, reflecting a 4.4% increase from the previous year [3]. Earnings Expectations - The consensus EPS estimate has been revised down by 1.41% over the last 30 days, indicating a bearish sentiment among analysts regarding the company's earnings prospects [4]. - Texas Roadhouse currently has an Earnings ESP of -2.28%, suggesting that the Most Accurate Estimate is lower than the Zacks Consensus Estimate [12]. Historical Performance - In the last reported quarter, Texas Roadhouse was expected to post earnings of $1.28 per share but actually reported $1.25, resulting in a surprise of -2.34% [13]. - Over the past four quarters, the company has only beaten consensus EPS estimates once [14]. Industry Context - In comparison, Cheesecake Factory (CAKE) is expected to report earnings of $0.99 per share for the same quarter, indicating a year-over-year decline of 4.8% [18]. - Cheesecake Factory's revenue is projected to be $948.89 million, up 3% from the previous year, and it has an Earnings ESP of +0.10%, suggesting a higher likelihood of beating the consensus EPS estimate [19][20].

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Gentherm, with a focus on how actual results compare to estimates, which could significantly influence the stock price [1][2]. Earnings Expectations - Gentherm is expected to report quarterly earnings of $0.57 per share, reflecting a year-over-year increase of +96.6% [3]. - Revenue is projected to be $374.72 million, representing a 6.2% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised down by 4.46% over the last 30 days, indicating a reassessment by analysts [4]. - The Most Accurate Estimate for Gentherm matches the Zacks Consensus Estimate, resulting in an Earnings ESP of 0% [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that a positive or negative reading indicates the likely deviation of actual earnings from the consensus estimate, with a strong predictor for positive readings [9][10]. - Gentherm currently holds a Zacks Rank of 3, making it challenging to predict an earnings beat conclusively [12]. Historical Performance - In the last reported quarter, Gentherm exceeded the expected earnings of $0.64 per share, achieving $0.73, which was a surprise of +14.06% [13]. - Over the past four quarters, Gentherm has beaten consensus EPS estimates twice [14]. Market Context - The automotive industry player Dana is expected to post earnings of $0.32 per share, indicating a year-over-year change of +28%, with revenues expected to decline by 20.4% to $1.86 billion [18][19]. - Dana's consensus EPS estimate has been revised up by 9.4% in the last 30 days, but it also has an Earnings ESP of 0.00% [19][20].

The market expects American Coastal Insurance (ACIC) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2025. This widely-known consensus outlook is important in assessing the company's earnings picture, but a powerful factor that might influence its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expect ...

Core Viewpoint - Akamai Technologies (AKAM) is expected to report a year-over-year increase in earnings and revenues for the quarter ended December 2025, with the actual results being crucial for its near-term stock price movement [1][2]. Earnings Expectations - The consensus estimate for Akamai's upcoming quarterly earnings is $1.75 per share, reflecting a year-over-year increase of +5.4% [3]. - Revenues are anticipated to reach $1.08 billion, which is a +5.6% increase from the same quarter last year [3]. Estimate Revisions - Over the last 30 days, the consensus EPS estimate has been revised 0.13% higher, indicating a positive reassessment by analysts [4]. - The Most Accurate Estimate for Akamai is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +1.02%, suggesting a bullish outlook from analysts [11]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive Earnings ESP reading is a strong predictor of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [9]. - Akamai currently holds a Zacks Rank of 3, which, along with the positive Earnings ESP, suggests a likelihood of beating the consensus EPS estimate [11]. Historical Performance - In the last reported quarter, Akamai exceeded the expected earnings of $1.64 per share by delivering $1.86, resulting in a surprise of +13.41% [12]. - The company has successfully beaten consensus EPS estimates in all of the last four quarters [13]. Industry Context - In comparison, DoorDash, Inc. (DASH) is expected to report earnings of $0.58 per share for the same quarter, indicating a year-over-year change of +75.8%, with revenues projected at $3.97 billion, up 38.2% from the previous year [17]. - However, DoorDash's consensus EPS estimate has been revised down by 3% over the last 30 days, resulting in an Earnings ESP of -1.72% and a Zacks Rank of 4 (Sell), making it difficult to predict an earnings beat [18].

Core Viewpoint - BridgeBio Pharma (BBIO) is expected to report a year-over-year increase in earnings driven by higher revenues, with the consensus outlook being crucial for assessing the company's earnings picture [1] Earnings Expectations - The consensus EPS estimate for BridgeBio Pharma is a loss of $0.74 per share, reflecting a year-over-year change of +43.5% [3] - Revenues are anticipated to reach $150.47 million, representing a significant increase of 2459% from the same quarter last year [3] Estimate Revisions - The consensus EPS estimate has been revised 1.1% higher in the last 30 days, indicating a collective reassessment by analysts [4] - The Most Accurate Estimate for BridgeBio Pharma is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -2.69%, suggesting a bearish outlook from analysts [12] Earnings Surprise History - In the last reported quarter, BridgeBio Pharma was expected to post a loss of $0.88 per share but actually reported a loss of -$0.95, resulting in a surprise of -7.95% [13] - Over the past four quarters, the company has only beaten consensus EPS estimates once [14] Industry Comparison - Bausch Health (BHC), another player in the Zacks Medical - Generic Drugs industry, is expected to report earnings of $1.21 per share, with a year-over-year change of +5.2% and revenues of $2.7 billion, up 5.7% from the previous year [18][19] - Bausch's consensus EPS estimate has been revised 0.6% higher, but a lower Most Accurate Estimate has resulted in an Earnings ESP of -8.84%, making it difficult to predict an earnings beat [19][20]

Core Viewpoint - Wall Street anticipates a year-over-year increase in earnings for Celsius Holdings Inc. (CELH) due to higher revenues, with actual results being crucial for stock price movement [1] Earnings Expectations - The consensus EPS estimate for Celsius is $0.19 per share, reflecting a year-over-year increase of +35.7% [3] - Expected revenues are $638.18 million, which is a significant increase of 92.1% from the previous year [3] Estimate Revisions - The consensus EPS estimate has been revised 0.59% higher in the last 30 days, indicating a positive reassessment by analysts [4] - The Most Accurate Estimate for Celsius is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +6.46% [12] Earnings Surprise Prediction - A positive Earnings ESP is a strong indicator of an earnings beat, especially when combined with a Zacks Rank of 1, 2, or 3 [10] - Celsius currently holds a Zacks Rank of 3, suggesting a likelihood of beating the consensus EPS estimate [12] Historical Performance - In the last reported quarter, Celsius exceeded the expected earnings of $0.28 per share by delivering $0.42, resulting in a surprise of +50.00% [13] - Over the past four quarters, Celsius has beaten consensus EPS estimates three times [14] Industry Context - In contrast, Medifast (MED), a competitor in the Zacks Food - Miscellaneous industry, is expected to report a loss of $0.76 per share, indicating a year-over-year change of -860% [18] - Medifast's expected revenue is $70.81 million, down 40.5% from the previous year [18]